Mucormycosis secondary prevention

Revision as of 18:54, 21 September 2017 by Mmir (talk | contribs) (Category)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search

Mucormycosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mucormycosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]

Overview

Posaconazole has been found to be an effective agent for secondary prevention of mucormycosis.

Secondary Prevention in Mucormycosis

  • Patients who respond to a parenteral lipid amphotericin B-based treatment, given for at least 3 weeks, are transitioned to oral posaconazole as maintenance/secondary prophylaxis with serial monitoring of posaconazole serum drug concentrations to ensure compliance and absorption of the antifungal.[1]
  • Lipid amphotericin B may achieve high levels in the human tissues, thus, intermittent doses of lipid amphotericin B (i.e., 5 mg/kg 3 times per week or possibly even 2 times per week) after at least 3 to 4 weeks of initial therapy as an alternative to posaconazole therapy may also be used.

References

  1. Kontoyiannis DP, Lewis RE (2011). "How I treat mucormycosis". Blood. 118 (5): 1216–24. doi:10.1182/blood-2011-03-316430. PMC 3292433. PMID 21622653.

Linked-in.jpg